The Na+K+-ATPase Inhibitor Marinobufagenin and Early Cardiovascular Risk in Humans: a Review of Recent Evidence

Michél Strauss,Wayne Smith,Olga V. Fedorova,Aletta E. Schutte

The Na+K+-ATPase Inhibitor Marinobufagenin and Early Cardiovascular Risk in Humans: a Review of Recent Evidence

2019

Michél Strauss
Wayne Smith
Olga V. Fedorova
Aletta E. Schutte

Purpose of Review This review synthesizes recent findings in humans pertaining to the relationships between marinobufagenin (MBG), a steroidal Na+/K+-ATPase inhibitor and salt-sensitivity biomarker, and early cardiovascular risk markers.

Keywords:

Endocrinology
Internal medicine
Diabetes mellitus
Na-K ATPase inhibitor
Biomarker (medicine)
Marinobufagenin
Medicine
Urinary system
salt intake
Disease
Nephrology
Blood pressure

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations